Stelazine

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Stelazine

Quick Facts

Property Description
Active ingredient Trifluoperazine (hydrochloride)
Form Tablet, Oral Concentrate, Solution for Injection
Pharmacological class Antipsychotic Agent (Neuroleptic)
Type/Classification First-Generation Antipsychotic (Typical, High-Potency)
Origin Synthetic phenothiazine derivative

What is the Active Ingredient in Stelazine?

The medicine known as Stelazine is a prescription-only medication whose sole active ingredient is Trifluoperazine, typically formulated as the hydrochloride salt. This compound is a powerful, synthetic substance classified within the phenothiazine derivative group. This single-ingredient product is manufactured for both the oral route (as a tablet or oral concentrate) and the parenteral route (as a solution for injection).

What Type of Antipsychotic is Trifluoperazine?

Trifluoperazine is formally classified as a First-Generation Antipsychotic (FGA), commonly identified as a Typical antipsychotic and belonging to the broader antipsychotic agent pharmacological class. This classification indicates its reliance on a classical mechanism of action, having been in clinical use since 1959.

Trifluoperazine is characterized as a high-potency agent within the typical class. Its status as a high-potency drug means it achieves its therapeutic effect at a comparatively lower dose, which is clinically recognized as differentiating it from low-potency FGAs.

What is the General Purpose of This Medication?

The overall purpose of this medicine is to promote mental stability and help control the symptoms associated with severe mental disturbance. Trifluoperazine exerts its stabilizing effect by acting as a dopamine receptor antagonist in the central nervous system. This focused action helps to modulate overactive signaling pathways. Its design is intended to reduce the intensity of highly disruptive experiences, such as acute phases of thought disorder or episodes of severe anxiety and agitation, assisting the patient in returning to a more rational and calm mental state.

Regulatory References

  1. MedlinePlus

What side effects are possible with Stelazine?

The safety profile of Trifluoperazine (Stelazine) is defined by adverse reactions documented in official government regulatory sources, grouped by their effect on physiological systems and severity.

Neurological and Movement-Related Effects

The most prominent safety domain relates to the nervous system, encompassing various forms of Extrapyramidal Symptoms (EPS) such as acute dystonia (muscle spasms), akathisia (motor restlessness), and pseudo-parkinsonism. Of serious concern is Tardive Dyskinesia (TD), a potentially irreversible syndrome of involuntary, repetitive movements, typically of the face and tongue, associated with long-term exposure. Regulatory labels also document the rare but critical event of Neuroleptic Malignant Syndrome (NMS), characterized by severe fever and muscle rigidity.

Systemic and Cardiovascular Safety

Documented serious systemic reactions include rare but serious blood dyscrasias (e.g., agranulocytosis). Cardiovascular risks include the potential for serious cardiac arrhythmias, such as QT prolongation and tachycardia. The drug class is associated with an increased risk of venous thromboembolism (VTE).

Time-Related Patterns and High-Risk Populations

Some effects show time-related patterns: acute dystonia is more common at the start of treatment, while TD risk increases with long-term use. Population-specific safety constraints are explicit, noting an increased risk of death when antipsychotic medications are used in older adults with dementia-related psychosis. Contraindications also apply to individuals with a comatose state or severe hepatic impairment, as stated in the prescribing information.

Overdose and Emergency Response

Overexposure to Stelazine (Trifluoperazine) is officially documented by regulatory authorities to manifest across major physiological systems. Manifestations may include severe Central Nervous System (CNS) effects such as sleepiness, profound drowsiness, loss of consciousness, and agitation. Motor disturbances like seizures, uncontrollable movements, and fever are also documented outcomes. Cardiovascular signs include an irregular heartbeat and life-threatening hypotension.

The regulatory standard dictates that immediate medical attention is required in all suspected overdose cases. Emergency services must be contacted immediately if the affected person has collapsed, had a seizure, has trouble breathing, or cannot be awakened.

Management of overexposure is primarily symptomatic and supportive, often requiring close hospital monitoring. No specific antidote is known. For treating severe hypotension, official prescribing information advises the use of pressor agents like Norepinephrine or Phenylephrine. Due to the risk of a paradoxical drop in blood pressure, the use of Epinephrine must be strictly avoided in the management of overdose-related hypotension.

Therapeutic Uses of Stelazine

Stelazine (Trifluoperazine) is generally used to help manage symptoms across two primary therapeutic domains: schizophrenia and related severe psychotic disorders, and the strategic management of severe anxiety in adults. This medication is applied across domains where additional symptomatic support is needed. It helps address symptom clusters that may become intense or disruptive, such as perceptual disturbances, fixed false beliefs, and disorganized thought. The medication supports general well-being during symptomatic phases and contributes to easing the overall symptom load.

For patients experiencing psychosis, this medication may assist with managing thought and behavioral disturbances, helping to restore mental stability. For severe anxiety, it is relevant when symptoms become temporarily overwhelming, such as intense tension and symptoms of increased neurological or muscular activity.

“This medication is commonly used to help with symptoms that create noticeable functional strain, offering symptomatic relief to help patients cope more steadily.”

Quick Fact: Relief for Symptom Categories
Psychotic Domain Symptom clusters that may become intense or disruptive.
Anxiety Domain Relevant in contexts marked by increased discomfort or tension.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Population Eligibility for Stelazine (Trifluoperazine)

Official regulatory documents define specific populations who are eligible to use Stelazine and groups for whom use is contraindicated or restricted.

Eligible Populations and Age Restrictions:

Stelazine is generally approved for use in adults for labeled indications. For children, use is generally restricted to ages 6 to 12 years for specific, limited conditions; safety and efficacy are not established for children under 6 years of age.

Absolute Contraindications (Must Not Use):

Stelazine is strictly prohibited for use in patients with a history of phenothiazine hypersensitivity, those with blood dyscrasias or bone marrow depression, and patients who are in a comatose or severely depressed central nervous system state. It is also contraindicated in patients with known subcortical brain damage.

Key Population Restrictions:

Population Group Restriction Status
Older Adults (65+) Contraindicated if they have dementia-related psychosis.
Pregnancy Not Recommended, especially during the third trimester.
Lactation Not Recommended; the drug is excreted in human milk.
Hepatic Function Contraindicated in patients with known significant liver damage.

What should I know about interactions with other medicines?

The official regulatory labeling for Stelazine (Trifluoperazine) establishes several clinically significant interaction patterns, primarily involving pharmacodynamic potentiation and specific prohibitions. Co-administration is formally contraindicated with Adrenaline (Epinephrine) when used to treat drug-induced hypotension. It is also prohibited in patients who are in a comatose or greatly depressed state due to the presence of large amounts of Central Nervous System (CNS) depressants, such as alcohol or strong analgesics, as this leads to a dangerous potentiation of effects. The combination with Desferrioxamine should not be used.

Documented Interaction Patterns

The drug's interaction profile includes documented additive effects that increase specific risks. Potentiation of CNS depression may occur with alcohol and other depressants, including hypnotics and anaesthetics. Cardiovascular risk is increased when combined with agents that prolong the Q-T interval or cause electrolyte imbalances, raising the hazard of ventricular arrhythmias. Additive effects on blood pressure lowering are also noted with antihypertensives.

Trifluoperazine may antagonise the therapeutic action of certain medicines, notably Levodopa and Guanethidine, and may also diminish the effect of Oral Anticoagulants. Furthermore, Antacids can reduce the absorption of the drug, leading to lower plasma concentrations. The co-administration of Lithium is officially associated with an increased risk of severe extrapyramidal side-effects and neurotoxicity, and may reduce phenothiazine serum levels to non-therapeutic concentrations.

Mechanism of Action

Trifluoperazine, the active compound in Stelazine, exerts its primary action through the antagonism of dopamine D2 receptors. This interaction occurs predominantly in the mesolimbic and mesocortical pathways of the central nervous system. The compound acts as a competitive antagonist, blocking the binding of endogenous dopamine to these specific receptor sites.

This D2 receptor blockade modulates key intracellular signaling cascades. Normally, dopamine binding is coupled to an inhibitory Gi protein that decreases the activity of adenylyl cyclase, resulting in reduced cAMP levels. By occupying the receptor, trifluoperazine prevents this normal inhibitory dopaminergic signaling. This prevents the normal cellular response, leading to a dampening of excessive dopaminergic activity in affected neural circuits and altered neurotransmission.

Additionally, trifluoperazine demonstrates secondary antagonist activity at alpha1-adrenergic and histamine H1 receptors, contributing to its overall pharmacological profile. The modulation of these diverse receptor systems alters the balance of neurochemical transmission, thereby impacting the homeostasis of neuronal circuits across the brain.

Dosage and Administration Information

Official Administration and Dosing Principles

Stelazine (trifluoperazine) is officially administered via the oral route, typically as a tablet or liquid concentrate, and via intramuscular injection (IM) for the rapid control of severe, acute symptoms. Oral doses are usually taken once or twice daily. Tablets may be consumed with or without food; taking them with food can help mitigate gastric upset. If the liquid concentrate is prescribed, it must be accurately measured and diluted immediately prior to intake with compatible liquids such as juice or water.


Standard Dosing and Time Constraints

For adults managing psychotic disorders, the usual starting dose is 2 mg to 5 mg twice daily, gradually increasing to a maintenance range, which often falls between 15 mg and 20 mg daily. The maximum labeled dose for this condition is 40 mg per day. When used for non-psychotic anxiety, the dosage is usually 2 mg to 4 mg daily, given in divided doses, and must not exceed 6 mg daily or a total treatment duration of 12 weeks.


Population and Procedural Rules

Official instructions require the starting dose for elderly or frail patients to be reduced by at least half and adjusted more slowly than for younger adults. For children aged 6 to 12 years under close supervision, the initial oral dosage is 1 mg once or twice daily, with the maximum generally not exceeding 15 mg daily. Should a dose be missed, the official instruction is to take it when remembered, unless it is almost time for the next scheduled dose, in which case the missed dose should be skipped to prevent taking a double dose. Discontinuation of high-dose therapy must be gradual.

Recent Clinical Evidence

Stelazine (Trifluoperazine): A Review of Recent Clinical Evidence

Stelazine, the brand name for trifluoperazine, is a conventional (first-generation) antipsychotic medication with a long history of use. Recent clinical reviews and studies continue to reinforce its established role while exploring safety and potential new applications.


Efficacy in Approved Indications

Clinical evidence consistently supports the efficacy of trifluoperazine for the management of schizophrenia, particularly in reducing positive symptoms such as delusions and hallucinations. Comparative reviews have suggested that trifluoperazine offers similar effectiveness to other typical antipsychotics. However, the quality of some older comparative evidence remains low, underscoring the need for modern, high-quality, randomized controlled trials.

For its other approved use as a short-term treatment for generalized non-psychotic anxiety, the clinical recommendation remains to use the lowest effective dose for no more than 12 weeks. This caution is due to the potential for developing tardive dyskinesia with prolonged use, a risk not commonly associated with first-line anxiety treatments.


Safety and Special Populations

Contemporary reviews of antipsychotic safety highlight an increased risk of mortality when these medications, including trifluoperazine, are used in elderly patients with dementia-related psychosis. This finding has led major regulatory bodies to issue a boxed warning against this specific use. Additionally, patients are advised of the potential for extrapyramidal symptoms (such as muscle stiffness and tremors), a common side effect of first-generation antipsychotics, with trifluoperazine sometimes showing a higher incidence of these effects compared to lower-potency alternatives.


Emerging Research

While trifluoperazine's primary use remains psychiatric, preclinical studies and early-phase trials have explored its potential in other areas. Research has investigated its anti-proliferative effects in models of pulmonary arterial hypertension and its antiviral activity against certain pathogens, often attributed to its mechanism of action as a calmodulin antagonist in addition to its dopamine receptor blockade. Further controlled human trials would be necessary to determine the clinical viability of these novel uses.

Key Studies & References

  1. TRIFLUOPERAZINE tablet, film coated: U.S. National Library of Medicine DailyMed Label (FDA)
  2. Psychosis and schizophrenia in adults: prevention and management - NICE Guideline [CG178] (2014, last updated 2025)

Frequently Asked Questions (FAQ)

Common questions about Stelazine (FAQ)


Q: Is Stelazine considered a strong antipsychotic compared to others?

Official drug classification states that Stelazine (trifluoperazine) is a high-potency First-Generation Antipsychotic (FGA). This means that it is effective at a relatively lower dose when compared to lower-potency drugs in the same class.


Q: Does Stelazine commonly cause long-term side effects?

Official labeling highlights that the most serious documented risk associated with long-term use is Tardive Dyskinesia (TD). This is a potentially persistent condition that involves involuntary movements. Official labeling indicates that this risk increases with the duration of use.


Q: What are extrapyramidal symptoms (EPS) and is Stelazine known to cause them?

Yes, Stelazine is known to cause EPS, which is a general term for a group of involuntary movement-related effects. These symptoms may include muscle stiffness, tremors (pseudo-parkinsonism), motor restlessness (akathisia), and muscle spasms (dystonia). These effects are documented in the official safety profile.


Q: Can Stelazine cause dry mouth?

Yes, dry mouth (xerostomia) is documented as a common side effect in official drug information. This is due to the drug's anticholinergic properties.


Q: Are there specific symptoms that signal a rare but serious reaction like Neuroleptic Malignant Syndrome (NMS)?

Regulatory documents state that NMS is a rare but life-threatening reaction. Key signals of NMS include high fever, severe muscle rigidity, sudden changes in mental status, and autonomic instability (such as irregular pulse or blood pressure). The nature of the condition indicates that if these symptoms appear, medical attention is required.


Q: Can abruptly stopping Stelazine cause withdrawal symptoms?

Yes, abruptly stopping this medication, particularly after long-term or high-dose therapy, may cause withdrawal symptoms. These symptoms can include nausea, vomiting, dizziness, and shakiness. Official instructions specify that the medication should be discontinued gradually.


Q: Does Stelazine affect the liver or require regular blood tests?

The medication is contraindicated for people with severe hepatic impairment ( significant liver damage). Furthermore, official warnings document rare but serious effects like blood dyscrasias (changes in blood components). These serious effects are the reason that regular monitoring may be required.


Q: What does the research say about the long-term use of Stelazine?

Clinical evidence generally supports the long-term effectiveness of Stelazine for its primary approved use. However, the official labeling warns that long-term use is associated with an increased risk of developing Tardive Dyskinesia ( TD).


Q: Can Stelazine cause low blood pressure?

Yes, official adverse reaction reports document that Stelazine can cause low blood pressure ( hypotension). This may cause dizziness or feeling faint, particularly when standing up quickly.


Q: What is the difference between Stelazine and other phenothiazine drugs?

Stelazine is classified as a high-potency phenothiazine antipsychotic. Compared to lower-potency phenothiazines, it is associated with a higher risk of EPS (involuntary movement disorders) but generally a lower risk of sedation and certain anticholinergic side effects.


Q: Is Stelazine generally used for short-term or long-term treatment?

The use is dependent on the condition being treated. It is used for the long-term management of schizophrenia. However, its use for generalized non-psychotic anxiety is officially restricted to short-term treatment, generally no more than 12 weeks.


Q: What is the duration of effect for a single dose of Stelazine?

The time it takes for half of the medication to be eliminated from the body ( elimination half-life) is typically reported in official pharmacokinetic data to be 10 to 20 hours. The medication can still be detected in the system for a time after this.


Q: Is Stelazine likely to cause weight gain?

Official documentation lists weight gain as an unusual or less common side effect for this medication.


Q: Is it normal to feel drowsy or dizzy when starting Stelazine?

Yes, drowsiness and dizziness are common side effects documented in official safety information, especially when treatment is first started.


Q: Is a change in libido or sexual function a known side effect of Stelazine?

Yes, decreased sexual ability and trouble having an orgasm are documented in the official product monograph as less common side effects.


Q: Can Stelazine affect a person's menstrual cycle?

Yes, missed menstrual periods ( amenorrhea) and changes in menstrual period are documented as possible side effects, according to official adverse reaction reports.


Q: Why does Stelazine sometimes cause breast enlargement or milk production?

This drug can cause hyperprolactinemia, which is an elevated level of the hormone prolactin. This hormonal change may lead to side effects such as breast swelling or pain and unusual milk secretion ( galactorrhea).


Q: Can Stelazine cause problems with body temperature regulation in extreme heat or cold?

Yes, this medication is documented to depress the hypothalamic thermoregulatory mechanism. Because of this, exposure to extreme temperatures (hot or cold) may cause problems with body temperature control, including hypothermia or hyperthermia.


Q: Does smoking or drinking coffee affect how Stelazine works in the body?

Official drug interaction information states that tobacco smoking may increase the clearance of phenothiazines from the body, which could reduce the medication's effectiveness. Coffee/caffeine is not explicitly documented in the same context.


Q: Can Stelazine increase sensitivity to sunlight (photosensitivity)?

Yes, official adverse reaction reports confirm that this medication can make skin more sensitive to the sun ( photosensitivity). Official safety information notes that precautions regarding sun exposure may be required.


Q: Does Stelazine carry a risk of dependence or addiction?

Regulatory bodies classify Stelazine as Not a controlled medication. It does not carry the same risk of dependence as controlled substances, but discontinuation symptoms can occur if the medication is stopped abruptly.


Q: What are the possible temporary symptoms if Stelazine is stopped suddenly?

Symptoms that may occur upon sudden discontinuation include nausea, vomiting, dizziness, and shakiness. Official instructions specify that stopping the medication abruptly should be avoided.


Q: How long does Stelazine stay in the system after the last dose?

The time it takes for half of the medication to be eliminated from the body ( elimination half-life) is typically reported in official pharmacokinetic data to be 10 to 20 hours. The medication can still be detected in the system for a time after this.


Q: Can Stelazine affect the results of other medical tests?

Yes, official instructions note that the care team should be informed if you are having a myelogram ( an x-ray examination of the spine). The drug should typically be temporarily discontinued before and after this procedure.


Q: Can Stelazine affect my ability to drive or operate machinery?

Yes, this medication may cause drowsiness and affect your thinking and movements, especially when treatment begins. Official warnings include a caution regarding the need to establish how the medication affects an individual before driving or operating machinery.


Q: Is it possible for Stelazine to cause changes in blood sugar?

Yes, official safety documents state that this medication may increase blood sugar levels. This is a documented concern, especially for patients who have diabetes or are at risk of developing it.


Q: Can Stelazine cause difficulty in urinating or urinary retention?

Yes, difficulty urinating and urinary retention ( the inability to completely empty the bladder) are documented as potential side effects, often related to the drug's anticholinergic properties.


Q: Does Stelazine interact with anticholinergic medications?

The drug itself has antimuscarinic ( anticholinergic) properties. Combining it with other medications that have similar effects can increase the risk of anticholinergic side effects like dry mouth, constipation, and urinary retention.


Q: Is there a risk of eye problems or vision changes with long-term Stelazine use?

Official adverse reaction reports document side effects including dry eyes, blurred vision, and potentially lens opacities with long-term use. Pupillary dilation (widening of the pupil) is also possible.


Q: Can Stelazine cause problems with balance or an unsteady feeling?

Yes, side effects documented in official information include problems with balance or walking and loss of balance or coordination. These effects are often related to dizziness or EPS.


Q: Does Stelazine interact with over-the-counter cold and flu medicines?

The medication carries warnings against combining it with any substance that causes CNS depression (drowsiness). Since many over-the-counter ( OTC) cold and flu medicines contain such ingredients (like antihistamines), this combination can increase the risk of drowsiness and dizziness.


Q: What is the risk of having a seizure while taking Stelazine?

It is officially documented that all antipsychotics can lower the seizure threshold. Official warnings include a caution regarding use in patients who have a history of seizures.


Q: Can Stelazine cause changes in appetite?

Yes, lack of appetite ( anorexia) is documented in official adverse reaction reports as a side effect of this medication.


Q: Is it true that Stelazine can make my skin turn color over time?

Yes, pigmentation changes and patchy skin color are documented as possible side effects, especially after long-term exposure to the drug.


Q: Can Stelazine cause problems with swallowing?

Yes, trouble swallowing ( dysphagia) is documented as a potential side effect in official adverse reaction reports.

How should Stelazine be stored and disposed of?

Official Storage and Disposal Requirements

Official regulatory documents define specific conditions for storing and disposing of Stelazine (trifluoperazine) to maintain its stability and prevent accidental exposure.

Formulation Required Storage Condition
Tablets Store at controlled room temperature, 20^circC to 25^circC (68^circF to 77^circF), protected from moisture and excessive heat.
Concentrate Store below 25^circC (77^circF) and protect from light.

The medicine must be kept in its tight container, tightly closed, and out of the reach of children to ensure child safety.

Regarding disposal, the preferred method for unused or expired Stelazine is through an authorized drug take-back program. If a program is unavailable, the medication should be mixed with an undesirable substance, such as dirt or used coffee grounds, placed in a sealed bag, and disposed of in the household trash. It should not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Stelazine found in:

A-Z Index: